- Home
- SKT vs VERA Comparison
SKT vs VERA Comparison
Compare SKT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKT | VERA |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | 1993 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SKT | VERA |
|---|---|---|
| Price | $34.11 | $42.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $36.17 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 02-24-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 8.00 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $575,140,000.00 | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | $35.99 | ★ N/A |
| Revenue Growth | ★ 10.01 | N/A |
| 52 Week Low | $28.69 | $18.53 |
| 52 Week High | $36.76 | $56.05 |
Technical Indicators
Market Signals| Indicator | SKT | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 44.21 |
| Support Level | $33.25 | $41.46 |
| Resistance Level | $34.50 | $44.96 |
| Average True Range (ATR) | 0.75 | 2.19 |
| MACD | 0.16 | -0.27 |
| Stochastic Oscillator | 76.85 | 28.81 |
Price Performance
Historical ComparisonAbout SKT Tanger Inc.
Tanger Inc is an owners and operators of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers, with a total gross leasable area of approximately 13.0 million square feet.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.